7020 Kit Creek Road
Research Triangle Park
About Locus BiosciencesLocus Biosciences’ novel approach to precision antimicrobials works by taking advantage of an immune system present in many bacteria called the CRISPR-Cas system. The CRISPR-Cas system protects bacteria from invaders such as viruses by creating a small strand of RNA called a CRISPR RNA, which matches a DNA sequence specific to a given invader. If the CRISPR RNA is matched to a complementary DNA sequence, the Cas proteins will cleave the invading DNA.
Co-Founder, CEO & Chairman of the Board: Paul Garofolo
Co-Founder, CSO & Chairman of Scienfic Advisors: Rodolphe Barrangou, PhD, MBA
Co-Founder & CTO: Dave Ousterout, PhD
Co-Founder & Scienfic Advisor: Charles Gersbach, PhD
Co-Founder & Scienfic Advisor: Chase Beisel, PhD
Please click here for Locus Biosciences' job opportunities.
5 articles with Locus Biosciences
Locus Biosciences Enters a Collaboration and License Agreement with Johnson & Johnson Innovation to develop CRISPR-Cas3 Bacteriophage Therapeutics
Locus Biosciences Inc., a biotechnology company developing precision antibacterial therapies, announced today that it has entered into an exclusive collaboration and license agreement with Janssen Pharmaceuticals, Inc. (Janssen)
Under the terms of the deal, Janssen is paying Locus $20 million up front. Locus will be eligible for up to a total of $798 million in development and commercial milestones, as well as royalties on any product sales.
Locus Biosciences acquires EpiBiome's high-throughput discovery platform to enhance its global leadership in CRISPR-engineered phage therapeutics
Acquisition significantly accelerates development of new products targeting antibiotic-resistant pathogens and microbiome indications
Locus Biosciences and IDbyDNA Partner to Develop Companion Diagnostic Test for Pseudomonas Aeruginosa Infection
Once LBx-PA01 reaches the market, the test will ensure that the medication will be given to patients with the greatest opportunity to benefit from it, improving patient outcomes and reducing the overall cost of treatment.
RTIS Ventures led the round, with additional financing from notable institutional investors Tencent Holdings Limited, Abstract Ventures, and the North Carolina Biotechnology Center, among others.